Physician profile
Hoe H Le
NPI 1811945611
$4,358.21
in general payments reported to CMS, 2019-2025
33 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $705 · 2021: $1,148 · 2022: $921 · 2023: $401 · 2024: $421 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,158.15 | 2019-2024 | |
| Lilly USA, LLC | $407.00 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $368.98 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $345.62 | 2019-2020 | |
| Pfizer INC. | $333.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.59 | 2021-2025 | Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $202.66 | 2023-2025 | Zoryve, Livalo |
| Novo Nordisk INC | $185.22 | 2020-2025 | Wegovy, Saxenda, Ozempic |
| Sunovion Pharmaceuticals INC. | $162.22 | 2019-2020 | |
| Abbott Laboratories | $134.29 | 2021-2023 | Aveir |
| Genentech USA, INC. | $98.23 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.26 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $51.79 | 2024 | Voquezna |
| Amarin Pharma, INC. | $51.30 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $49.41 | 2024 | Flucelvax |
| Astellas Pharma US INC | $44.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.18 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.64 | 2021-2023 | Tradjenta, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $36.43 | 2022 | |
| Esperion Therapeutics, INC. | $24.42 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.99 | 2022 | |
| Nevro Corp. | $22.71 | 2023 | Senza |
| Edwards Lifesciences Corporation | $19.69 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $19.47 | 2023 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $19.26 | 2020 | |
| Amgen INC. | $18.66 | 2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $16.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.65 | 2019 | |
| Horizon Therapeutics Plc | $16.37 | 2021 | |
| Mannkind Corporation | $15.80 | 2020 | |
| Merck Sharp & Dohme LLC | $13.88 | 2020 | |
| Vanda Pharmaceuticals INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoe Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.